Envista (NYSE:NVST) PT Lowered to $19.00

Envista (NYSE:NVST) had its price target trimmed by Bank of America from $22.00 to $19.00 in a research note published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

NVST has been the topic of a number of other research reports. Piper Sandler cut their target price on Envista from $18.00 to $16.00 and set a neutral rating on the stock in a research report on Tuesday, July 30th. The Goldman Sachs Group dropped their target price on Envista from $20.00 to $17.50 and set a sell rating on the stock in a report on Friday, May 3rd. Evercore ISI lowered their price objective on Envista from $19.00 to $18.00 and set an outperform rating for the company in a research report on Thursday. Robert W. Baird lowered their price target on Envista from $19.00 to $17.00 and set a neutral rating for the company in a report on Monday, July 22nd. Finally, Stifel Nicolaus cut their price target on shares of Envista from $20.00 to $18.00 and set a buy rating on the stock in a research note on Tuesday, July 30th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $19.14.

Envista Price Performance

NVST stock traded down $0.32 during trading on Thursday, hitting $16.18. The stock had a trading volume of 4,447,904 shares, compared to its average volume of 2,442,982. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.27 and a quick ratio of 1.93. The company’s 50-day moving average price is $16.82 and its two-hundred day moving average price is $19.45. The stock has a market capitalization of $2.78 billion, a P/E ratio of -22.47, a PEG ratio of 14.74 and a beta of 1.31. Envista has a twelve month low of $15.15 and a twelve month high of $33.84.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business had revenue of $633.10 million during the quarter, compared to analyst estimates of $646.88 million. During the same quarter in the previous year, the company posted $0.43 EPS. The firm’s revenue was down 4.4% on a year-over-year basis. As a group, research analysts predict that Envista will post 1.15 EPS for the current fiscal year.

Institutional Trading of Envista

Hedge funds have recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after buying an additional 621 shares during the period. Signaturefd LLC grew its stake in shares of Envista by 1,297.9% during the fourth quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock valued at $63,000 after acquiring an additional 2,427 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Envista by 1,420.3% during the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after acquiring an additional 2,940 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Envista by 538.0% in the fourth quarter. Quadrant Capital Group LLC now owns 3,209 shares of the company’s stock worth $77,000 after acquiring an additional 2,706 shares in the last quarter. Finally, Innealta Capital LLC purchased a new position in Envista in the second quarter valued at about $78,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.